Germany’s Expert Committee for Prescription was not convinced of the value of making Perrigo’s progestogen-only contraceptive pill available OTC, according to the recently-published minutes of its 23 January meeting.
Among many concerns which led the committee to unanimously reject Perrigo’s switch application for desogestrel (75μg) for oral use was...
Welcome to HBW Insight
Create an account to read this article
Already a subscriber?